Latest News

The PRIMA technology is today one of the most discussed topics in the field of vision restoration, ophthalmic medical devices and clinical trials of retinal implants. It is often called an “eye prosthesis”, “bionic eye”, “artificial retina” or “retinal implant”, but it is technically more accurate to speak of a subretinal wireless implant that replaces the function of lost photoreceptors in the central retina. That is why topics like “PRIMA Stargardt”, “retinal implant for Stargardt disease”, “new treatments for central vision loss”, “how to regain reading ability with macular degeneration” and “clinical trials of the bionic eye” are quickly gaining attention in Ukraine as well.

At the same time, it is important to separate the facts immediately. The best‑known PRIMA outcome — 27 out of 32 patients who were able to read again one year after implantation — was published for patients with geographic atrophy from dry age‑related macular degeneration, not yet as a proven final result specifically for Stargardt disease. The Stargardt indication is being officially expanded, and a separate clinical study for inherited retinal degenerations has already been registered. So PRIMA for Stargardt is not fantasy but a real development direction; however, as of April 2026 it remains under clinical investigation.

What PRIMA is and why the implant is called a breakthrough

PRIMA is a central vision restoration system made of two main components: a miniature subretinal implant and specialized glasses with a camera and an infrared projector. The camera captures the scene, a processor enhances contrast, brightness and scale, and then the glasses transmit data and power to the implant using infrared light. The implant itself sits under the retina and stimulates preserved cells, bypassing the damaged photoreceptors.

The main innovation of PRIMA is its fully wireless operation. Unlike older systems that required cables and external power sources, PRIMA works as a light‑sensitive photovoltaic microchip. This reduced the surgical complexity of the device and is one reason the technology is seen as one of the most promising solutions in the “vision implant”, “modern medical devices for the blind”, “wireless retinal implant” and “electronic eye prosthesis” segments.

Another important fact is the device size. The implant is roughly 2×2 mm and contains 378 light‑sensitive pixels. This is not a “return to normal vision” in the classical sense, but this architecture has already allowed patients to distinguish letters, numbers, words and large high‑contrast objects again. For people who have lost central vision, this means not just a technical improvement but a real return of functional skills — reading, spatial orientation, recognizing signs and everyday items.

PRIMA clinical trials: the numbers that made the technology known

The strongest evidence for PRIMA’s efficacy came from the PRIMAvera (NCT04676854) program. The study included 38 patients with geographic atrophy from dry age‑related macular degeneration, aged over 60, with very low visual acuity in at least one eye. After 12 months, 32 participants were evaluated. 26 of 32 patients showed a clinically significant improvement in visual acuity, and 27 of 32 were able to read letters, numbers and words at home using prosthetic vision. The average improvement was about 5 lines on the visual acuity chart, and the best individual result reached 12 lines or 59 letters.

The practical meaning of these results is huge. Participants reported being able to read books, product labels, signs and subway markings. With the magnification function, the PRIMA glasses can scale the image up to 12 times, and in some cases acuity with digital enhancements reached the equivalent of 20/42. For the medical technology market this became the first convincing example that a retinal implant can restore not just light perception but actual central vision suitable for reading.

Safety must also be mentioned separately. According to a publication in The New England Journal of Medicine, 19 participants experienced 26 serious adverse events related to the procedure or device. At the same time, 81% of these events occurred in the first two months after surgery, and 95% of them resolved within two months from onset. This does not mean the technology carries zero risk, but it indicates that the risks were mostly early, manageable and compatible with continued use of the system.

Can PRIMA help with Stargardt disease

This is where the topic is especially important for a Ukrainian audience. Stargardt disease is an inherited retinal disorder that causes progressive loss of central vision, often beginning in adolescence or early adulthood. The National Eye Institute explicitly notes that the most typical symptom is a gradual deterioration of central vision, which makes reading, face recognition and tasks requiring fine detail difficult. Official sources also emphasize that currently there is no approved treatment for Stargardt disease.

That is why PRIMA attracts such interest. The mechanism of Stargardt disease partially overlaps with the logic behind PRIMA: photoreceptors in the macula degenerate, but other retinal cells remain sufficiently preserved for some time to be electrically stimulated. Science Corporation’s official page explicitly states that the company is investigating the use of PRIMA for patients with Stargardt, and in March 2026 the company announced a clinical program expansion to Stargardt disease and retinitis pigmentosa. In addition, ClinicalTrials.gov lists a separate study NCT07266584 evaluating the safety and efficacy of PRIMA products in patients with inherited macular‑affecting retinal degeneration, including Stargardt.

What this means for patients in Ukraine

For Ukraine this topic has not only scientific but practical value. Queries like “Stargardt treatment in Ukraine”, “clinical trials of retinal implant”, “where to get Stargardt diagnosed”, “bionic eye cost”, “how to join an international clinical trial”, “new technologies for vision restoration” and “can you read after a retinal implant” are entirely logical. But patients need to understand that PRIMA is not yet a routinely available commercial solution for Stargardt and remains an innovative medical device at the clinical development stage.

As of March–April 2026 the company reports a submitted CE mark application in the EU and a parallel submission to the FDA for regulatory approval, with the first commercial launch expected primarily in Europe. This means Ukrainian patients following topics like “PRIMA implant in Europe”, “where the retinal implant is available”, “Stargardt clinical trial” or “new treatments for central blindness” should already focus on international centers, official clinical trial registries, genetic diagnostics and consultations with specialized retinal specialists.

Conclusion

PRIMA is not just a headline about an “eye prosthesis” but a real medical device platform that has already demonstrated the ability to restore reading to a portion of patients with severe central vision loss. The most striking figure — 27 of 32 patients — is clinically confirmed, but so far for geographic atrophy in dry AMD. For Stargardt disease the technology looks very promising because new clinical trials are already officially targeting inherited retinal degenerations. For Ukrainian patients this means one thing: PRIMA has moved from futuristic promises into the realm of evidence‑based medicine, but the path to wide availability for Stargardt is still ongoing.